2010
DOI: 10.4161/hv.6.11.12851
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
10
0

Year Published

2011
2011
2017
2017

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 19 publications
(14 citation statements)
references
References 15 publications
4
10
0
Order By: Relevance
“…Preliminary immunogenicity studies, conducted in Japan (http://www.mhlw.go.jp/kinkyu/kenkou/influenza/dl/infu091016-01.pdf) and elsewhere [13], showed acceptable immunogenicity from a single dose of the unadjuvanted vaccine in healthy adults. Similar results were obtained with 2009 influenza A (H1N1) monovalent adjuvanted vaccines in healthy young adults, with at least a 90% seroconversion rate following a single dose [4, 5, 6]. …”
Section: Introductionsupporting
confidence: 69%
“…Preliminary immunogenicity studies, conducted in Japan (http://www.mhlw.go.jp/kinkyu/kenkou/influenza/dl/infu091016-01.pdf) and elsewhere [13], showed acceptable immunogenicity from a single dose of the unadjuvanted vaccine in healthy adults. Similar results were obtained with 2009 influenza A (H1N1) monovalent adjuvanted vaccines in healthy young adults, with at least a 90% seroconversion rate following a single dose [4, 5, 6]. …”
Section: Introductionsupporting
confidence: 69%
“…This long-term persistence data supplements already available data that the AS03-adjuvanted H1N1 2009 pandemic influenza vaccine (antigen content: 3.75 or 1.9 μg HA) induces HI antibody responses that meet all CHMP guidance criteria for pandemic influenza vaccines, 21 d after one or two doses (administered 21 d apart) in different age groups. [1][2][3][4]9 The HI antibody results in this study should be interpreted in the light of assay variability inherent for HI assays.…”
Section: Discussionmentioning
confidence: 96%
“…This vaccine was proven to be highly immunogenic (fulfilling the European and US regulatory guidance criteria for pandemic influenza vaccines) with a clinically acceptable safety profile in different populations. [1][2][3][4] This manuscript presents data on the persistence of Hemagglutination Inhibition (HI) immune response against the a/ california/7/2009 strain, six and 12 mo after adults received one dose (n = 138) or two doses (n = 102; 21 d apart) of a 3.75 μg Hemagglutinin antigen as03-adjuvanted H1N1 2009 vaccine (NcT00968526). Two hundred forty subjects (18-60 y: 120; > 60 y: 120) were vaccinated.…”
Section: Introductionmentioning
confidence: 99%
“…Age as a negative determinant of the HI response to A(H1N1)pdm09 vaccines is well described in the elderly (3, 10, 13, 15) and, albeit less extensively, in nonelderly adults (13, 15, 2628). This, in conjunction with the age-related decline in the HI and memory B-cell responses observed here, indicates that vaccine responses are heterogeneous between these age segments in nonelderly adults.…”
Section: Discussionmentioning
confidence: 99%